The U.S. Food and Drug Administration has expanded the approval of Sarepta Therapeutics' Elevidys (delandistrogene ...
The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for patients with ...
On the heels of a Phase III flop for Pfizer’s Duchenne muscular dystrophy gene therapy candidate, the FDA will decide whether ...
The U.S. Food and Drug Administration has expanded its previous approval for Sarepta Therapeutics’ gene therapy to treat ...
The Food and Drug Administration on Thursday approved Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular ...
Thursday, the FDA approved labeled indication for Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Elevidys (delandistrogene ...
Shares of Sarepta SRPT rose nearly 34% in after-market trading on Thursday after it announced that the FDA approved the expanded use of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys.
The US Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of muscular ...
The US Food and Drug Administration (FDA) has granted expanded approval to Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy to treat patients aged four years and older with a ...
Sarapeta Therapeutics Inc.’s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has ...
The U.S. FDA approved expanded use of Sarepta's gene therapy for Duchenne muscular dystrophy, spiking shares. A Texas judge ...
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted ...